Zhang, Jian
Wang, Xiaojia
Wang, Xian
Hui, Aimin
Wu, Zhuli
Tian, Ling
Xu, Changjiang
Yang, Yuchen
Zhang, Wenjing
Hu, Xichun
Article History
Received: 20 February 2021
Accepted: 19 May 2021
First Online: 9 June 2021
Declarations
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. The study was approved by the Ethics Committee of Fudan University Shanghai Cancer Center (No. 1806186–8-1808), Cancer Hospital of the University of Chinese Academy of Sciences (No. IRB-[2019]619), and Sir Run Run Shaw Hospital (No. 20190927–14).
: Informed consent was obtained from all individuals who participated in the study.
: The study was initiated, funded, and sponsored by Avanc Pharmaceutical Co., Ltd. Jian Zhang, Xiaojia Wang, Xian Wang, and Xichun Hu declare no potential conflicts of interest. Aimin Hui is a full-time employee of Fosun Pharma USA Inc. Zhuli Wu, Changjiang Xu, Yuchen Yang, and Wenjing Zhang are full-time employees of Beijing Fosun Pharmaceutical Research and Development Co., Ltd. Ling Tian is a full-time employee of Avanc Pharmaceutical Co., Ltd.